Intrinsic Value of S&P & Nasdaq Contact Us

Nuvalent, Inc. NUVL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$137.44
+30.9%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Nuvalent, Inc. (NUVL) has a negative trailing P/E of -18.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 35.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -5.42%, forward earnings yield 2.85%. PEG 0.50 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (84/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.50); analyst target implies upside (+30.9%).
  • Forward P/E 35.1 — analysts expect a return to profitability with estimated EPS of $2.99 for FY2029.
  • PEG Ratio 0.50 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -5.42% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 2.85% as earnings recover.
  • Analyst consensus target $137.44 (+30.9% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 55/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
57/100
SG Score
View full scorecard →
VALUE
84/100
Price-to-Earnings & upside
Proven by this page
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
MOAT
40/100
→ Income
GROWTH
15/100
→ Income
INCOME
N/A
No coverage

Valuation Snapshot — NUVL

Valuation Multiples
P/E (TTM)-18.5
Forward P/E35.1
PEG Ratio0.50
Forward PEG0.50
P/B Ratio6.29
P/S Ratio0.00
EV/EBITDA-21.9
Per Share Data
EPS (TTM)$-5.66
Forward EPS (Est.)$2.99
Book Value / Share$16.62
Revenue / Share$0.00
FCF / Share$-3.66
Yields & Fair Value
Earnings Yield-5.42%
Forward Earnings Yield2.85%
Dividend Yield0.00%
Analyst Target$137.44 (+30.9%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2019 -76.7 0.00 -52.46 0.00 -
2020 -29.5 -0.18 -13.69 0.00 -
2021 -9.0 -0.04 1.46 0.00 -
2022 -18.1 0.80 3.19 0.00 -
2023 -33.9 -1.08 6.12 0.00 -
2024 -19.9 -0.25 4.86 0.00 -
2025 -17.2 -0.35 5.86 0.00 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2019 $-0.24 $0.00 $-11.81M -
2020 $-0.30 $0.00 $-14.56M -
2021 $-2.13 $0.00 $-46.34M -
2022 $-1.65 $0.00 $-81.85M -
2023 $-2.17 $0.00 $-126.22M -
2024 $-3.93 $0.00 $-260.76M -
2025 $-5.85 $0.00 $-425.38M -

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-5.56 $-7.43 – $-4.50 $14.1M $549.83K – $32.88M 13
2027 $-4.24 $-6.83 – $-2.30 $186.41M $105.21M – $258.37M 13
2028 $-0.93 $-4.15 – $2.73 $528.62M $522.99M – $534.25M 13
2029 $3.01 $0.65 – $6.04 $919.56M $364.72M – $1.63B 11
2030 $4.69 $1.01 – $9.42 $1.21B $478.84M – $2.14B 5
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message